Board of directors
IDDI has established a versatile Board of Directors to guide the organization.
Henri Tassenoy is a Consultant in business management, trained by the Belgian Chamber of Accountants and "Bank" postgraduate. With approximately 12 years spent in the former General de Banque in various departments, Finance Management for 6 years of its subsidiary Capital Development: Former Synerfi. For 15 years, Henri Tassenoy has served as Independent Administrator of IDDI and companies active in various fields: advertising, real estate, wholesale trade. Henri provides consultancy in financial management, pre-acquisition auditing, restructuring and entrepreneurship.
Alain Herrera, MD, is currently Consultant in Oncology. He has created Alain Oncology Consulting (AOC) in November 2008 after heading for ten years the Oncology business at Sanofi-aventis where he was successively VP responsible for Global Oncology Business Strategy and Development (2007-2008) and Head of Global Oncology Franchise (1998-2007) and contributed to the worldwide registration of two products: oxaliplatin (Eloxatin®) and rasburicase (Fasturtec®/Elitek®) as well as the Gastric and Head & Neck indications for docetaxel (Taxotere®). His previous responsibilities within Pharmaceutical industry include the roles of Chairman of Chiron Therapeutics Europe, Director of Chiron B.V, Corporate VP and Member of Management Council of Chiron Corporation and Managing Director at Pierre Fabre Oncology Laboratories. Besides these duties, Dr. Herrera has also been since 1991 Hematologist Consultant at Antoine Beclere Hospital and Beaujon Hospital. He is an active member of ASCO (American Society of Clinical Oncology) and ESMO (European Society of Medical Oncology) and serves on the Executive Committee of ESH (European School of Hematology) since 1985.
Marc Melviez holds a master’s degree in business engineering from the Solvay Business School. His career started at KPMG, where he was a financial auditor, and at Management Science America (MSA), where he was software applications specialist. He later created and managed several software companies, which he drove to fast growth and high profitability. He is the Group CEO of Luciad NV, which he joined during the scale-up phase. Luciad supplies geospatial software to the Defense, Security and Aerospace industries worldwide. In addition to his leadership role at Luciad, he serves on the board of W.IN.G (Wallonia Innovation and Growth) by Digital Wallonia, an organization that helps evaluate and fund promising digital start-ups in the French-speaking region of Belgium, and on the Boards of several other companies. Marc is also an experienced instrument-rated pilot qualified on high performance aircraft.
Jean-Pierre Bizzari, M.D., served as Executive Vice-President, Group Head, and Clinical Oncology Development (U.S., Europe, and Asia/Japan) at Celgene from 2008 to 2015. He has been involved in the clinical development of several anticancer agents such as Taxotere®, Eloxatin®, Abraxane®, Irinotecan® (CPT-11). As a world-renowned oncology expert, he is a member of the Scientific Advisory Board of the French National Cancer Institute (INCa) and European Organization of Research and Treatment of Cancer (EORTC) and Chairman of the New Drug Advisory Committee. Mr. Bizzari is also an active Board Member in various biotech companies, such as Transgene in France, Halozyme Therapeutics and Pieris Pharmaceuticals in the US. Jean-Pierre Bizzari joined the pharmaceutical industry in 1983 as Head of Oncology at the Institut de Recherches Internationales SERVIER (France). He then joined Rhône-Poulenc Rorer in 1993 as Vice President of Clinical Oncology, based in Paris and moved to Collegeville (PA – USA) in 1997. From 2002 until 2008, Mr. Bizzari served as Vice President of Clinical Oncology Development at Sanofi-Aventis in Malvern, PA before joining Celgene. Jean-Pierre Bizzari holds a medical degree specialized in oncology from the University of Nice (France) and has trained successively at the Pitié-Salpêtrière hospital in Paris, at Ontario Cancer Institute, and Montreal Mac Gill Cancer Center in Canada.
Gery Lefebvre is Investment Manager at SRIW SA. He has several non-executive memberships in biotech start-ups/spin-off and companies active in the life science and industrial business.
In 1995, Gery Lefebvre graduated in Business Administration from HEC-ULg and started immediately his career in Credit Management with Atradius and then in Corporate Banking at HSBC Paris.
In 2002, he obtained a post-graduate Master in Taxation from HEC-ULg. After that he moved to Albemarle Europe where he was responsible for Treasury Management and Working Capital Optimization.
Between 2009 and 2014, he was the CFO of Belgian Advanced Technology Systems SA.
Damien Tremolet is Executive Director of IDDI. He holds degrees in information technology from Paris XI and management from ICHEC Brussels. He worked as IT Project Leader in the space, energy and railway industries before joining the pharmaceutical arena as IT Manager and Director of Operations for IDDI. He led Client Services in France and Belgium and set up an operational branch in Paris for Perceptive Informatics. He is keen to build long-term partnerships with clients and to promote the use of advanced methodology and integrated technology in clinical trials. Damien enjoys outdoor activities particularly trail running and sailing.
Marc Buyse is founder and Chairman of IDDI and Associate Professor of Biostatistics at the Universiteit Hasselt. He holds degrees in engineering and statistics from Brussels University (ULB), management from the Cranfield School of Management (Cranfield, UK) and a doctorate in biostatistics from Harvard University (Boston, MA). He was the recipient of several research fellowships in Belgium, the US and Japan. He was President of the International Society for Clinical Biostatistics, President of the Quetelet Society, and Fellow of the Society for Clinical Trials. He worked at the EORTC (European Organization for Research and Treatment of Cancer) in Brussels and at the Dana Farber Cancer Institute in Boston prior to founding IDDI in 1991. He has published extensively in the fields of clinical trial methodology, meta-analysis, statistical detection of fraud, validation of biomarkers and surrogate endpoints, and drug development in oncology and ophthalmology